All In Biotech

Drug Trial Radar · NCT07937449

The Efficacy and Safety of DLBS3233 in Adults With Prediabetes

A Randomized, Double-Blind, Parallel, Controlled, Non-Inferiority Study to Evaluate the Efficacy and Safety of DLBS3233 in Adults With Prediabetes

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jul 7, 2025

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
Collaborators
PT Equilab International
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.

Conditions

  • Prediabetes

Interventions

  • DLBS3233Drug

    DLBS3233 will be given into two different groups; 1 capsule of DLBS3233 100 mg once daily and 2 capsules of DLBS3233 100 mg once daily.

  • Metformin XRDrug

    Metformin XR 500 mg will be given 1 tablet twice daily as a comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes of HbA1c levelsTime frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Internal Medicine, Dr. Soetomo Regional Public Hospital

    Surabaya, East Java, Indonesia

  • Equilab International

    Jakarta, Jakarta Special Capital Region, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.